Myristoyl lysophosphatidylcholine is a biomarker and potential therapeutic target for community-acquired pneumonia
There is no gold standard for evaluating the severity of community-acquired pneumonia (CAP), and it is still based on a score. This study aimed to use the metabolomics method to find promised biomarkers in assessing disease severity and potential therapeutic targets for CAP. The result found that th...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Redox Biology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231722003287 |
| _version_ | 1811315854611054592 |
|---|---|
| author | Wengang Nan Fen Xiong Hong Zheng Chen Li Cong Lou Xiong Lei Huizhen Wu Hongchang Gao Yuping Li |
| author_facet | Wengang Nan Fen Xiong Hong Zheng Chen Li Cong Lou Xiong Lei Huizhen Wu Hongchang Gao Yuping Li |
| author_sort | Wengang Nan |
| collection | DOAJ |
| description | There is no gold standard for evaluating the severity of community-acquired pneumonia (CAP), and it is still based on a score. This study aimed to use the metabolomics method to find promised biomarkers in assessing disease severity and potential therapeutic targets for CAP. The result found that the metabolites in the plasma samples of CAP patients had significantly different between the acute phase and the remission phase, especially lysophosphatidylcholine (LPCs) in glycerophospholipids, whose levels are negatively linked to the severity of the disease. Subsequently, the two key metabolites of myristoyl lysophosphatidylcholine (LPC 14:0) and LPC 16:1 were screened. We analyzed the predictive performance of the two metabolites using Spearman-related analysis and ROC curves, and LPC14:0 showed more satisfactory diagnostic performance than LPC16:1. Then we explored the protective role and mechanism of LPC 14:0 in animal and cell models. The results showed that LPC 14:0 could inhibit the LPS-induced secretion of IL-1β, IL-6, and TNF-α, lower the ROS and MDA levels, and decreased the depletion of SOD and GSH, thereby reducing lung tissue and cell damage, such as down-regulating the protein level in BALF, lung W/D ratio, MPO activity, and apoptosis. We found that LPC 14:0 inhibited LPS-induced inflammatory response and oxidative stress, and the above protection was achieved by inhibiting LPS-induced activation of the NLRP3 inflammasome. LPC 14:0 may serve as a novel biomarker for predicting the severity of CAP. In addition, our exploration of the role of LPC 14:0 in animal and cellular models has reinforced its promise as a therapeutic target to improve the clinical efficacy for CAP. |
| first_indexed | 2024-04-13T11:37:37Z |
| format | Article |
| id | doaj.art-83d6f3ed5f7844a3aec2b1616bfd72a1 |
| institution | Directory Open Access Journal |
| issn | 2213-2317 |
| language | English |
| last_indexed | 2024-04-13T11:37:37Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Redox Biology |
| spelling | doaj.art-83d6f3ed5f7844a3aec2b1616bfd72a12022-12-22T02:48:23ZengElsevierRedox Biology2213-23172022-12-0158102556Myristoyl lysophosphatidylcholine is a biomarker and potential therapeutic target for community-acquired pneumoniaWengang Nan0Fen Xiong1Hong Zheng2Chen Li3Cong Lou4Xiong Lei5Huizhen Wu6Hongchang Gao7Yuping Li8Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, ChinaOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, ChinaOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, ChinaOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, ChinaDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China; Corresponding author. Institute of Metabonomics & Medical NMR, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Corresponding author. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang Street, Wenzhou, 325000, China.There is no gold standard for evaluating the severity of community-acquired pneumonia (CAP), and it is still based on a score. This study aimed to use the metabolomics method to find promised biomarkers in assessing disease severity and potential therapeutic targets for CAP. The result found that the metabolites in the plasma samples of CAP patients had significantly different between the acute phase and the remission phase, especially lysophosphatidylcholine (LPCs) in glycerophospholipids, whose levels are negatively linked to the severity of the disease. Subsequently, the two key metabolites of myristoyl lysophosphatidylcholine (LPC 14:0) and LPC 16:1 were screened. We analyzed the predictive performance of the two metabolites using Spearman-related analysis and ROC curves, and LPC14:0 showed more satisfactory diagnostic performance than LPC16:1. Then we explored the protective role and mechanism of LPC 14:0 in animal and cell models. The results showed that LPC 14:0 could inhibit the LPS-induced secretion of IL-1β, IL-6, and TNF-α, lower the ROS and MDA levels, and decreased the depletion of SOD and GSH, thereby reducing lung tissue and cell damage, such as down-regulating the protein level in BALF, lung W/D ratio, MPO activity, and apoptosis. We found that LPC 14:0 inhibited LPS-induced inflammatory response and oxidative stress, and the above protection was achieved by inhibiting LPS-induced activation of the NLRP3 inflammasome. LPC 14:0 may serve as a novel biomarker for predicting the severity of CAP. In addition, our exploration of the role of LPC 14:0 in animal and cellular models has reinforced its promise as a therapeutic target to improve the clinical efficacy for CAP.http://www.sciencedirect.com/science/article/pii/S2213231722003287Community-acquired pneumoniaAcute lung injuryBiomarkerMetabolomicsNLRP3 inflammasome |
| spellingShingle | Wengang Nan Fen Xiong Hong Zheng Chen Li Cong Lou Xiong Lei Huizhen Wu Hongchang Gao Yuping Li Myristoyl lysophosphatidylcholine is a biomarker and potential therapeutic target for community-acquired pneumonia Redox Biology Community-acquired pneumonia Acute lung injury Biomarker Metabolomics NLRP3 inflammasome |
| title | Myristoyl lysophosphatidylcholine is a biomarker and potential therapeutic target for community-acquired pneumonia |
| title_full | Myristoyl lysophosphatidylcholine is a biomarker and potential therapeutic target for community-acquired pneumonia |
| title_fullStr | Myristoyl lysophosphatidylcholine is a biomarker and potential therapeutic target for community-acquired pneumonia |
| title_full_unstemmed | Myristoyl lysophosphatidylcholine is a biomarker and potential therapeutic target for community-acquired pneumonia |
| title_short | Myristoyl lysophosphatidylcholine is a biomarker and potential therapeutic target for community-acquired pneumonia |
| title_sort | myristoyl lysophosphatidylcholine is a biomarker and potential therapeutic target for community acquired pneumonia |
| topic | Community-acquired pneumonia Acute lung injury Biomarker Metabolomics NLRP3 inflammasome |
| url | http://www.sciencedirect.com/science/article/pii/S2213231722003287 |
| work_keys_str_mv | AT wengangnan myristoyllysophosphatidylcholineisabiomarkerandpotentialtherapeutictargetforcommunityacquiredpneumonia AT fenxiong myristoyllysophosphatidylcholineisabiomarkerandpotentialtherapeutictargetforcommunityacquiredpneumonia AT hongzheng myristoyllysophosphatidylcholineisabiomarkerandpotentialtherapeutictargetforcommunityacquiredpneumonia AT chenli myristoyllysophosphatidylcholineisabiomarkerandpotentialtherapeutictargetforcommunityacquiredpneumonia AT conglou myristoyllysophosphatidylcholineisabiomarkerandpotentialtherapeutictargetforcommunityacquiredpneumonia AT xionglei myristoyllysophosphatidylcholineisabiomarkerandpotentialtherapeutictargetforcommunityacquiredpneumonia AT huizhenwu myristoyllysophosphatidylcholineisabiomarkerandpotentialtherapeutictargetforcommunityacquiredpneumonia AT hongchanggao myristoyllysophosphatidylcholineisabiomarkerandpotentialtherapeutictargetforcommunityacquiredpneumonia AT yupingli myristoyllysophosphatidylcholineisabiomarkerandpotentialtherapeutictargetforcommunityacquiredpneumonia |